Coherus Oncology (CHRS)

• Market cap: $195M
• 1 day: -1.18%
• 5 days: 1.82%
• 1 month: 2.44%
• 3 months: 78.69%
• 6 months: 63.11%
• Year to date: 20%
• 1 year: 125.5%
• 5 years: -89.88%
• 10 years: -94.15%
• Sector: Healthcare
• Industry: Biotechnology

About: Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Employees: 177